Comparison of Clinical Outcomes in Patients With Localized or Locally Advanced Urothelial Carcinoma Treated With Neoadjuvant Chemotherapy Involving Gemcitabine-Cisplatin and High Dose-Intensity MVAC

DOI: https://doi.org/10.21203/rs.3.rs-164451/v1

Abstract

Purpose

To compare the efficacy and safety of high dose-intensity combination of methotrexate, vinblastine, adriamycin and cisplatin (HD MVAC) with gemcitabine plus cisplatin (GC) as a neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) or locally advanced upper tract urothelial cancer (UTUC).

Patients and Methods

A retrospective analysis was conducted for patients with UC (cT2-4aN0-1M0) who received NAC from January 2011 and December 2017 at Asan Medical Center. Pathologic complete response (pCR), down-staging (<ypT2 and no N upstaging), disease-free survival (DFS), OS and safety were compared for each regimen.

Results

Out of a total of 277 patients, 176 patients received GC and 41 patients received HD MVAC. With the exception of age (patients receiving GC were younger; p=0.002), other baseline characteristics were well balanced between groups. pCR rates were 27.0% for GC and 22.6% for HD MVAC (p=0.62), and down-staging rate was 50.8% for GC and 58.1% for HD MVAC (p=0.47). There were no differences in OS (72.1% vs 73.1% for GC vs HD MVAC; p=0.58) and DFS (54.9% vs 63.3% for GC vs HD MVAC; p=0.21) at 3 years. HD MVAC with prophylactic G-CSF was associated with a higher incidence of febrile neutropenia (p<0.001) than GC. The NAC regimen was not an independent prognostic factor for OS.

Conclusions

Oncologic outcomes were not significantly different between the GC and HD MVAC when used as NAC in MIBC/UTUC.

Full Text

This preprint is available for download as a PDF.

Tables

Due to technical limitations, table 1, 2, 3, 4 and 5 is only available as a download in the Supplemental Files section.